These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 38158945)

  • 1. [Features of the course of COVID-19 in patients with type 2 diabetes mellitus].
    Karaseva EA; Martynov VA; Filatova TE; Maleev VV; Grishin VY; Pronin NS; Verbitskaya EI; Popova VI
    Ter Arkh; 2023 Dec; 95(11):913-918. PubMed ID: 38158945
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk factors for COVID-19 case fatality rate in people with type 1 and type 2 diabetes mellitus: A nationwide retrospective cohort study of 235,248 patients in the Russian Federation.
    Shestakova MV; Vikulova OK; Elfimova AR; Deviatkin AA; Dedov II; Mokrysheva NG
    Front Endocrinol (Lausanne); 2022; 13():909874. PubMed ID: 36017317
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glucometabolic Perturbations in Type 2 Diabetes Mellitus and Coronavirus Disease 2019: Causes, Consequences, and How to Counter Them Using Novel Antidiabetic Drugs - The CAPISCO International Expert Panel.
    Popovic DS; Papanas N; Koufakis T; Kotsa K; Mahmeed WA; Al-Rasadi K; Al-Alawi K; Banach M; Banerjee Y; Ceriello A; Cesur M; Cosentino F; Firenze A; Galia M; Goh SY; Janez A; Kalra S; Kempler P; Kapoor N; Lessan N; Lotufo P; Rizvi AA; Sahebkar A; Santos RD; Stoian AP; Toth PP; Viswanathan V; Rizzo M
    Exp Clin Endocrinol Diabetes; 2023 May; 131(5):260-267. PubMed ID: 36693416
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Change in glucose-lowering medication regimens in individuals with type 2 diabetes mellitus during the COVID-19 pandemic in Germany.
    Jacob L; Rickwood S; Rathmann W; Kostev K
    Diabetes Obes Metab; 2021 Apr; 23(4):910-915. PubMed ID: 33319440
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mortality and other adverse outcomes in patients with type 2 diabetes mellitus admitted for COVID-19 in association with glucose-lowering drugs: a nationwide cohort study.
    Pérez-Belmonte LM; Torres-Peña JD; López-Carmona MD; Ayala-Gutiérrez MM; Fuentes-Jiménez F; Jorge Huerta L; Muñoz JA; Rubio-Rivas M; Madrazo M; Garcia MG; Montes BV; Sola JF; Ena J; Ferrer RG; Pérez CM; Ripper CJ; Lecumberri JJN; Acedo IEA; Canteli SP; Cosío SF; Martínez FA; Rodríguez BC; Pérez-Martínez P; Ramos-Rincón JM; Gómez-Huelgas R;
    BMC Med; 2020 Nov; 18(1):359. PubMed ID: 33190637
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Non-insulin anti-diabetic agents in patients with type 2 diabetes and COVID-19: A Critical Appraisal of Literature.
    Singh AK; Singh R; Saboo B; Misra A
    Diabetes Metab Syndr; 2021; 15(1):159-167. PubMed ID: 33352455
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacotherapeutic considerations for the management of diabetes mellitus among hospitalized COVID-19 patients.
    Hasan SS; Kow CS; Bain A; Kavanagh S; Merchant HA; Hadi MA
    Expert Opin Pharmacother; 2021 Feb; 22(2):229-240. PubMed ID: 33054481
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of New Glucose-Lowering Drugs on Risk of Heart Failure in Type 2 Diabetes: A Network Meta-Analysis.
    Kramer CK; Ye C; Campbell S; Retnakaran R
    JACC Heart Fail; 2018 Oct; 6(10):823-830. PubMed ID: 30196071
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Demographic and Clinical Profiles of Type 2 Diabetes Mellitus Patients Initiating Canagliflozin Versus DPP-4 Inhibitors in a Large U.S. Managed Care Population.
    Grabner M; Peng X; Geremakis C; Bae J
    J Manag Care Spec Pharm; 2015 Dec; 21(12):1204-12. PubMed ID: 26679969
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dipeptidyl Peptidase-4 Inhibitors, Glucagon-like Peptide-1 Receptor Agonists, and Sodium-Glucose Cotransporter-2 Inhibitors and COVID-19 Outcomes.
    Foresta A; Ojeda-Fernandez L; Macaluso G; Roncaglioni MC; Tettamanti M; Fortino I; Leoni O; Genovese S; Baviera M
    Clin Ther; 2023 Apr; 45(4):e115-e126. PubMed ID: 36933975
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dipeptidyl-peptidase (DPP)-4 inhibitors and glucagon-like peptide (GLP)-1 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus.
    Hemmingsen B; Sonne DP; Metzendorf MI; Richter B
    Cochrane Database Syst Rev; 2017 May; 5(5):CD012204. PubMed ID: 28489279
    [TBL] [Abstract][Full Text] [Related]  

  • 12. European Society of Cardiology/Heart Failure Association position paper on the role and safety of new glucose-lowering drugs in patients with heart failure.
    Seferović PM; Coats AJS; Ponikowski P; Filippatos G; Huelsmann M; Jhund PS; Polovina MM; Komajda M; Seferović J; Sari I; Cosentino F; Ambrosio G; Metra M; Piepoli M; Chioncel O; Lund LH; Thum T; De Boer RA; Mullens W; Lopatin Y; Volterrani M; Hill L; Bauersachs J; Lyon A; Petrie MC; Anker S; Rosano GMC
    Eur J Heart Fail; 2020 Feb; 22(2):196-213. PubMed ID: 31816162
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Noninsulin-based antihyperglycemic medications in patients with diabetes and COVID-19: A systematic review and meta-analysis.
    Nassar M; Abosheaishaa H; Singh AK; Misra A; Bloomgarden Z
    J Diabetes; 2023 Feb; 15(2):86-96. PubMed ID: 36690377
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of anti-diabetic drugs and COVID-19 outcomes in patients with diabetes mellitus type 2 and cardiomyopathy.
    Dimnjaković J; Buble T; Ivanko P; Pristaš I; Brborović O; Brborović H
    Sci Rep; 2024 Mar; 14(1):7227. PubMed ID: 38538694
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of Glucagon-Like Peptide-1 Receptor Agonist vs Dipeptidyl Peptidase-4 Inhibitor Use With Mortality Among Patients With Type 2 Diabetes and Advanced Chronic Kidney Disease.
    Chen JJ; Wu CY; Jenq CC; Lee TH; Tsai CY; Tu HT; Huang YT; Yen CL; Yen TH; Chen YC; Tian YC; Yang CW; Yang HY
    JAMA Netw Open; 2022 Mar; 5(3):e221169. PubMed ID: 35254430
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sex Differences in Cardiovascular Effectiveness of Newer Glucose-Lowering Drugs Added to Metformin in Type 2 Diabetes Mellitus.
    Raparelli V; Elharram M; Moura CS; Abrahamowicz M; Bernatsky S; Behlouli H; Pilote L
    J Am Heart Assoc; 2020 Jan; 9(1):e012940. PubMed ID: 31902326
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Heart failure in patients with type 2 diabetes mellitus: assessment with echocardiography and effects of antihyperglycemic treatments.
    Iwakura K
    J Echocardiogr; 2019 Dec; 17(4):177-186. PubMed ID: 31617144
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors as monotherapy or add-on to metformin in patients with type 2 diabetes mellitus: A systematic review and meta-analysis.
    Wang Z; Sun J; Han R; Fan D; Dong X; Luan Z; Xiang R; Zhao M; Yang J
    Diabetes Obes Metab; 2018 Jan; 20(1):113-120. PubMed ID: 28656707
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association between use of novel glucose-lowering drugs and COVID-19 hospitalization and death in patients with type 2 diabetes: a nationwide registry analysis.
    Ferrannini G; Lund LH; Benson L; Rizzo M; Almahmeed W; Rosano GMC; Savarese G; Cosentino F
    Eur Heart J Cardiovasc Pharmacother; 2022 Dec; 9(1):10-17. PubMed ID: 35963647
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Myocardial infarction in type 2 diabetes using sodium-glucose co-transporter-2 inhibitors, dipeptidyl peptidase-4 inhibitors or glucagon-like peptide-1 receptor agonists: proportional hazards analysis by deep neural network based machine learning.
    Yamada T; Iwasaki K; Maedera S; Ito K; Takeshima T; Noma H; Shojima N
    Curr Med Res Opin; 2020 Mar; 36(3):403-409. PubMed ID: 31855074
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.